Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K dated July 1, 2026. The filing primarily serves to disclose updates to the Company's corporate deck regarding clinical trial progress for its gene editing programs.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on clinical developments and regulatory disclosures.
Material Changes and Clinical Updates
- ELIMINATE-B Study (Chronic Hepatitis B): The Company announced clinical highlights for PBGENE-HBV. Liver biopsy data demonstrated a direct elimination of cccDNA, resulting in a 1-log (10-fold) reduction in cccDNA-derived transcripts.
- FUNCTION-DMD Trial (Duchenne Muscular Dystrophy): The Company activated a second clinical site at Washington University School of Medicine in St. Louis, Missouri, to commence the FUNCTION-DMD trial evaluating PBGENE-DMD.
Guidance, Outlook, and Risks
Outlook: The Company targets year-end 2026 for the next program update on the ELIMINATE-B study and for initial safety data from the FUNCTION-DMD trial.
Risks: The filing includes a standard cautionary statement regarding forward-looking statements. It references risks detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and Quarterly Reports on Form 10-Q for the period ended March 31, 2026. The Company explicitly states it has no obligation to update forward-looking statements unless required by law.
Investor Verification Checklist
- Verify the specific liver biopsy data and statistical significance of the 1-log reduction in cccDNA-derived transcripts in the updated corporate deck.
- Confirm the enrollment status and timeline for the FUNCTION-DMD trial at the new Washington University site.
- Review the referenced Form 10-K (fiscal year 2025) and Form 10-Q (Q1 2026) for detailed risk factors and financial health, as this 8-K contains no financial data.
- Monitor for the targeted year-end 2026 data readouts for both the ELIMINATE-B and FUNCTION-DMD programs.